•  
  •  
  •  
  •  

2025-09-28 19:35:26

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Umiya Mobile Limited Strengthens Market Presence with 36 New Stores Post IPO
  • Avantel Ltd to inaugurate new facility on Oct 2, 2025
  • Solarium Green Energy Ltd receives orders worth Rs. 18.77 crores
  • Capricorn Systems Global Solutions Ltd receives order for supply of broken rice
  • Anand Rayons Ltd receives approval for STAPII trademark

Keywords Selected:  GranulesIndia

Stock Report

  • Granules India Ltd receives 1 observation from USFDA for Chantilly facility
  • Granules India Ltd receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1
  • Granules India earns Gold Rating in First-Ever Corporate-Level EcoVadis Assessment Ranks in the Top 5% Globally Across All Industries
  • Granules India Announces Closing of Acquisition of Senn Chemicals, Strengthening Capabilities in Peptide Therapeutics and CDMO Services
  • Granules India enters the high growing peptide segment and CDMO business by acquiring Senn Chemicals AG
  • Granules India Ltd posts consolidated PAT of Rs. 117.60 crores in Q3 FY2025
  • Granules India Limited announces FDA Approval for ADHD Treatment, Addressing Drug Shortages in the U.S.
  • Granules' Net Zero Commitment Validated and Approved by Science Based Targets Initiative
  • Granules India Ltd posts consolidated PAT of Rs. 97.23 crores in Q2 FY2025
  • Granules India Ltd announces ANDA Approval for Bupropion Hydrochloride Extended-Release Tablets
  • Granules India Unveils 'Breast Health Express' Mobile Unit
  • Granules India's Gagillapur Facility Completes US FDA Inspection with Six Observations
  • Granules India Limited receives ANDA approval for Glycopyrrolate Oral Solution
  • Granules India Ltd Q1 FY25 consolidated PAT higher at Rs. 134.64 crores
  • Granules India Ltd Q4 FY2024 consolidated profit rises to Rs. 129.64 crores
  • Granules India Limited announced ANDA Approval for Colchicine Capsules
  • US FDA audit of Granules India's Unit V facility results in Zero 483s
  • Granules India Ltd consolidated Q3 FY24 PAT higher at Rs. 125.65 crores
  • Granules India Ltd received ANDA Approval for Pantoprazole Sodium Delayed-Release Tablets
  • Granules India Limited Received ANDA Approval for Sildenafil for Oral Suspension
  • Granules India Ltd received ANDA Approval for Esomeprazole Magnesium Delayed-Release Capsules
  • Granules India Ltd received ANDA Approval for Losartan and Hydrochlorothiazide Tablets
  • Granules India Limited received approval from Brazilian Health Regulatory Agency ANVISA
  • Granules India Limited received Accreditation Certificate of Foreign Drug Manufacturer from PMDA

Latest Post

  • Umiya Mobile Limited Strengthens Market Presence with 36 New Stores Post IPO
  • Avantel Ltd to inaugurate new facility on Oct 2, 2025
  • Solarium Green Energy Ltd receives orders worth Rs. 18.77 crores
  • Capricorn Systems Global Solutions Ltd receives order for supply of broken rice
  • Anand Rayons Ltd receives approval for STAPII trademark


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024